A prognostically favorable association for IDO expression has also previously been observed in breast cancer (22, 24), ovarian cancer (60), renal cell cancer (21), vulvar cancer (61), and lung cancer (51). This evidence concerns the gene IDO1 and ovarian carcinoma.